Apollo Hospitals to spin off digi health, pharmacy business

Apollo Hospitals is demerging its omnichannel pharma and digital health businesses into a new entity, aiming for a separate listing. This move creates India's largest omnichannel pharmacy platform with a revenue target of ₹25,000 crore by FY27. The promoter family will hold approximately 36.5% in the new company, with Shobana Kamineni as the executive chairperson.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yzOGd41
via IFTTT

Read More

Wockhardt activates Zaynich push, eyes global licensing deals

Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing deals while preparing for potential solo commercialization in key markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AQmcYDl
via IFTTT

Read More

After a robust march, pharma exports slow

India's pharmaceutical exports experienced a modest 1.5% growth in April and May, following a significant 31.2% surge in March driven by year-end targets and anticipation of US tariffs. Despite pricing pressures and regulatory scrutiny, shipments to the US rose 20.4% to $10.5 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6crY4N
via IFTTT

Read More

Torrent Pharma set to finalise JB Chemicals buyout in 15-18 months

Torrent Pharmaceuticals is set to acquire JB Chemicals & Pharmaceuticals, with the deal expected to finalize in 15-18 months, pending regulatory approvals. The acquisition, primarily debt-funded, aims to enhance Torrent's presence in the Indian market, particularly in high-growth segments like cardiac and gastroenterology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BtDPmXi
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

Alembic Pharmaceuticals has received final USFDA approval. This approval is for its generic Doxorubicin Hydrochloride Liposome injection. The injection comes in strengths of 20 mg/10 mL and 50 mg/25 mL. It is used to treat ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The market size for this injection is estimated at USD 29 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CWsE2vP
via IFTTT

Read More

Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation

Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dNEK69B
via IFTTT

Read More

Clear & Legible: Labelling on drug packets to get a booster

Concerns arose regarding medicine labels. Consumers struggled to read expiry dates. The shiny surface of strips posed readability issues. The Drugs Consultative Committee addressed the matter. A sub-committee will examine packaging in detail. They will assess regulations for packaging suppliers. The government considers voice-assisted QR codes. Braille cards on strips are also under consideration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFbvXEj
via IFTTT

Read More

Torrent Pharma to buy controlling stake in JB Chemicals from KKR for Rs 25,689 crore

Torrent Pharmaceuticals is set to acquire a 46.39% controlling stake in JB Chemicals and Pharmaceuticals from KKR for ₹11,917 crore, valuing JB Pharma at ₹25,689 crore. Following the acquisition, Torrent plans a merger, pending regulatory approvals, and will launch an open offer to public shareholders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vPMNtoa
via IFTTT

Read More

Torrent, JB Chemicals finalising steps for two-stage merger, combine may find place in pharma big 5

Torrent Pharmaceuticals and JB Chemicals & Pharmaceuticals are finalizing merger terms in a two-stage deal. Torrent will first acquire KKR's 47.84% stake in JB Chemicals for approximately ₹13,433 crore, financed by global banks, potentially triggering an open offer. The subsequent merger aims to create synergies, positioning Torrent among India's top five pharma players with a combined value of ₹1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2PNfkOi
via IFTTT

Read More

From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations

Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide clinically strong and tech-enabled healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9SlAZRG
via IFTTT

Read More

Eli Lilly to roll out diabetes medicine in prefilled pen

Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offers a convenient, once-weekly administration. It contains four fixed doses. This launch intensifies competition with Novo Nordisk's Wegovy. Mounjaro's dual mechanism may offer superior efficacy. The availability of all six dosage options will support personalized treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKveCG0
via IFTTT

Read More

Lupin launches generic chronic constipation treatment drug in US

Mumbai-based Lupin Ltd has introduced its generic Prucalopride tablets in the United States. This launch follows approval from the US health regulatory body. The tablets, available in 1 mg and 2 mg strengths, treat chronic idiopathic constipation in adults. These tablets are bioequivalent to Takeda Pharmaceuticals' Motegrity tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wL2lOsr
via IFTTT

Read More

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

Eli Lilly announced that India’s drug regulator has approved its Mounjaro KwikPen, a pre-filled injector pen for weight loss and diabetes treatment. Previously available only in vials, Mounjaro will now be offered in six dose strengths, enhancing convenience and competitiveness against Novo Nordisk’s newly launched Wegovy, which also features a user-friendly pen format.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MSnrD85
via IFTTT

Read More

Pharma companies may lose licence if drugs fail tests

The health ministry is considering strict actions, including immediate license suspensions, for drugmakers producing substandard drugs. This proposal follows concerns about quality control and aims to safeguard public health. Pharma lobby groups have raised objections, citing technical issues and questioning the standards of government testing laboratories, while advocating for a stronger recall mechanism.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GeNpgHz
via IFTTT

Read More

Lupin gets USFDA nod for generic chronic constipation treatment drug

Lupin Limited has received the United States Food and Drug Administration approval for its generic version of Prucalopride tablets. These tablets are used for treating chronic idiopathic constipation. The approved strengths are 1 mg and 2 mg. This generic medicine is bioequivalent to Takeda Pharmaceuticals' Motegrity tablets. Lupin will manufacture the product at its Goa facility in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UYvFxtq
via IFTTT

Read More

Bharat Biotech, GSK to halve price of malaria vaccine by 2028

Drugmakers Bharat Biotech and GSK will reduce the price of their malaria vaccine, Mosquirix, to $5 per dose by 2028, more than halving the current cost. This price cut, driven by process improvements and expanded production, aims to improve access to the vaccine in sub-Saharan Africa, where malaria deaths are high. Gavi supports the vaccine's rollout in twelve African countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/M2JmEpV
via IFTTT

Read More

China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs

Indian pharmaceutical and biotech sectors are experiencing early benefits from the global shift away from China, driven by the China+1 strategy. Companies are seeing increased conversion of inquiries into pilot projects and small contracts, particularly from large pharmaceutical firms seeking supply chain diversification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A1WoVil
via IFTTT

Read More

Weight-loss drug Wegovy starts at ₹17,345 in India

Novo Nordisk launches Wegovy, a weekly weight-loss injectable, in India. The drug is available in five dosages, costing between Rupees 17,345 and Rupees 26,015. It aims for chronic weight management and reduces cardiovascular risks. Experts highlight its potential despite the price. Mounjaro, another weight-loss drug, is priced lower. Weight-loss drugs are game changers for obese patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FBKQWxD
via IFTTT

Read More

A big fat fight has just broken out in India

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and diabetes rates, with Mounjaro showing significant weight loss in trials. Wegovy boasts cardiovascular benefits and a competitive pricing strategy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oIRKluT
via IFTTT

Read More

Favipiravir drug shows promise against Chandipura virus in preclinical studies by NIV

Favipiravir offers hope against the Chandipura virus. Studies by the National Institute of Virology show promising results. The drug reduces viral load in infected animals. Chandipura outbreaks have occurred in India, affecting children. A major outbreak happened in 2024. Clinical trials on humans are pending. Research is underway for a vaccine. Current treatment focuses on managing symptoms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3G4jsPE
via IFTTT

Read More

Novo Nordisk aims for heavy sales in India with Wegovy

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescription brand sales. Keytruda, a breakthrough anti-cancer drug from MSD India (part of the US Merck group), is currently the No. 1 in prescription brands, with annual revenue exceeding Rs 1,600 crore, according to market sources.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bZer730
via IFTTT

Read More

Sickle cell anaemia test kits priced less than Rs 50 in govt's bid to eradicate the disease

Sickle cell anaemia diagnosis is now more accessible in India. The government reduced the price of diagnostic kits to under Rs 50. ICMR validated 35 point-of-care tests. This follows a health technology assessment. The National Health Mission instructed states to procure kits at lower prices. This initiative supports the National Sickle Cell Elimination Programme.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RBOyZFU
via IFTTT

Read More

ICMR's NIIH develops simple point of care test for haemophilia A, Von Willebrand Disease

A cost-effective point-of-care test kit has been developed in India for early diagnosis of haemophilia A and Von Willebrand Disease, offering a more accessible alternative to expensive lab tests. This innovation, costing just Rs 582 compared to Rs 2,086 for current methods, could detect over 83,000 undiagnosed cases and save the health system approximately Rs 42 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QdPWxjF
via IFTTT

Read More

From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations

Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide clinically strong and tech-enabled healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nlP6arJ
via IFTTT

Read More

Amazon launches home diagnostic services in 6 cities through app

Amazon India has launched Amazon Diagnostics, an at-home lab test booking service, integrating it with Amazon Medical alongside Pharmacy and Clinic services. Partnering with Orange Health Labs, the service is available in major cities like Bengaluru, Delhi, Mumbai and Hyderabad, covering over 450 PIN codes. Customers can book tests, schedule appointments, and access digital reports via the Amazon app.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yHpagqk
via IFTTT

Read More

From pimples to peptides: How Gen Z turned the dermatologist into a beauty guru

Urban India witnesses a surge in dermatology clinic visits, driven by teenagers and young adults seeking solutions for everyday skin concerns beyond chronic conditions. Social media influence and access to information fuel this trend, with consumers actively choosing science-backed skincare. This shift reflects a broader movement towards evidence-based self-care, impacting the skincare market and prompting early dermatologist visits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zk3jqNu
via IFTTT

Read More

Deadline diet India's young workforce faces cardiac scare

Young Indians are increasingly facing heart issues. Doctors report a rise in cardiac cases among those in their 20s and 30s. Stress, lack of sleep, and unhealthy lifestyles are major factors. Sedentary jobs and poor diets contribute to the problem. Even post-Covid inflammation increases the risk. Sales of heart-related drugs have significantly increased.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CzwOp8c
via IFTTT

Read More

Emcure Pharma to acquire remaining 20.42% stake in Zuventus Healthcare for Rs 724.9 cr

Emcure Pharmaceuticals will acquire the remaining 20.42% stake in Zuventus Healthcare Ltd from minority shareholders for ₹724.9 crore, a move approved by its board. This acquisition, expected to close in the September quarter of FY26, will make Zuventus a wholly-owned subsidiary. Emcure aims to fully consolidate Zuventus financially, driving long-term value creation and unlocking synergies within its domestic business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fV9J362
via IFTTT

Read More

Stress at work? Doctors see rise in heart diseases among young executives

Young Indians are increasingly facing heart issues. Cardiologists are alarmed by the rising cases in people in their 20s and 30s. Stress, sleep deprivation, and unhealthy lifestyles are major contributors. Hospitals report more young professionals with cardiovascular diseases. Experts suggest early screenings and lifestyle changes. Companies are now offering heart check-ups for employees.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XlhMg1k
via IFTTT

Read More

The Wegovy effect: A weight-loss drug reshapes the lives of teens battling obesity

Facing relentless bullying and health issues linked to obesity, some American teens are turning to Wegovy, a weight-loss drug initially approved for adults. While many see it as a chance for a healthier future, concerns linger about long-term safety and potential side effects. The experiences of four teens highlight both the benefits and challenges of this treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BnSX4bH
via IFTTT

Read More

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch in March. The company is prioritizing meeting the growing demand for the diabetes and weight-loss drug in the country, where obesity and diabetes rates are rising.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MHEYcfC
via IFTTT

Read More

US approves Gilead's twice-yearly injection to prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus. An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tuwbNhZ
via IFTTT

Read More

Global Autism Therapy Framework for 90 crore children: How India cracked 144-year-old world problem,

Pinnacle, an Indian autism therapy network, gains global recognition. It is acknowledged for its innovative, mother-led, and AI-enabled approach. International institutions and organizations are seeking collaborations. Pinnacle's framework is adaptable and inclusive. It focuses on measurable care and dignity-first delivery. The model is designed for diverse languages and geographies. Pinnacle invites global partnerships to expand its reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zWYqiMG
via IFTTT

Read More

6 anti-cancer foods to add to your daily chai

Make your chai time healthier by adding foods known to offer anti-cancer benefits. These simple, everyday ingredients can help fight harmful cells, boost immunity, and support overall well-being while you enjoy your cup of tea.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GU9nDfs
via IFTTT

Read More

With no upgradation plan, several small drug companies may shut operations

Many small pharma companies in India may shut down. They did not meet the deadline for upgrading facilities. This is as per new Good Manufacturing Practices. Only 1,700 out of 6,000 units submitted upgrade plans. Closures could lead to job losses. There are also concerns about potential drug shortages and price increases. The government may initiate audits and regulatory actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ALDiIyo
via IFTTT

Read More

Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in India

Abbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin, its combination sitagliptin/metformin, and the extended-release version, marketed as Januvia, Janumet, and Janumet XR. This collaboration aims to leverage Abbott's extensive reach to ensure continued access to these diabetes treatments for the large diabetic and pre-diabetic population in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EYXHb27
via IFTTT

Read More

Suraksha Diagnostics to invest Rs 200 cr to set up over 20 centres across east India

Suraksha Diagnostics plans a significant expansion. The company will invest Rs 200 crore. This investment will establish over 20 advanced imaging centers. These centers will be located across eastern India. The expansion aims to improve diagnostic services. It will focus on tier 2 and tier 3 cities. This initiative will enhance healthcare access in smaller towns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5o6KicY
via IFTTT

Read More

Glenmark gets five observations from USFDA for Monroe plant

Glenmark Pharmaceuticals announced that its Monroe, North Carolina manufacturing plant received a Form 483 with five observations from the USFDA following a GMP inspection conducted in June 2025. The company stated that the observations are procedural and don't involve data integrity issues. Glenmark is committed to addressing the concerns and will respond to the USFDA within the required timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6Cainw1
via IFTTT

Read More

Torrent Pharma keen to break into big league

Torrent Pharma, currently seventh in India, is aimingto break into the top three drugmakers within five years through strategic acquisitions. Bolstered by consistent growth in the Indian market, the company plans further investments following past deals like Curatio Healthcare. Expansion includes doubling its medical representatives to 7,000 for better market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fZeT3gD
via IFTTT

Read More

US pharma bets big on China to snap up potential blockbuster drugs

U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CFk64zZ
via IFTTT

Read More

Zydus Healthcare appoints Swati Dalal MD

Zydus Lifesciences Ltd. has appointed Swati Dalal as an additional director and Managing Director of its subsidiary, Zydus Healthcare Ltd., effective June 16, 2025, for a five-year term. Dalal brings over 30 years of experience, most recently serving as Managing Director of Abbott India Ltd. Her career includes leadership roles at Wockhardt Nutrition, Boots, Knoll, Solvay, and Abbott.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nZ4AphT
via IFTTT

Read More

Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler

Lupin Limited partners with Sino Universal Pharmaceuticals. They will commercialize Tiotropium dry powder inhaler in China. This inhaler treats Chronic Obstructive Pulmonary Disease. Sino Universal will seek regulatory approvals. Lupin will manufacture the product. This collaboration expands Lupin's presence in China. It aims to improve respiratory disease treatment. The partnership focuses on providing high-quality healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zq8uATM
via IFTTT

Read More

Online pharmacies could face stricter check-ups

Amid rising concerns over unverified prescriptions and a surge in online pharmacies, the government is intensifying regulation and scrutiny on platforms promising medicine delivery within minutes. Complaints regarding bypassed safeguards like age verification have prompted this action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MY96ZRe
via IFTTT

Read More

Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma

Kirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vtFqsNg
via IFTTT

Read More

Sun Pharma gets eight observations from USFDA for Halol plant

Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant in Gujarat. The USFDA conducted a Good Manufacturing Practices (GMP) inspection at the facility from June 2-13, 2025. The Form 483, issued at the inspection's conclusion, highlights conditions that may violate the Food, Drug, and Cosmetic Act and related regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WTN8zrP
via IFTTT

Read More

Delhi HC refuses to halt Sun Pharma’s Pruease tables sales over trademark row

The Delhi High Court has denied RSPL Health's petition to stop Sun Pharmaceutical Industries from selling Pruease tablets, a constipation relief medication. RSPL Health, which sells sanitary napkins under the trademark 'Pro-ease,' claimed trademark infringement. The court dismissed the plea, stating that the products have distinct trade channels and there is no likelihood of confusion among consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KpBfVUR
via IFTTT

Read More

Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the Board

Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes on additional responsibility for the North America business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vpt4WX8
via IFTTT

Read More

Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by Bharat Biotech, including Phase 3 trials and manufacturing. This collaboration aims to address the urgent need for a Shigella vaccine due to rising antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JvfzKWV
via IFTTT

Read More

Pharma body opposes entry curbs on medical representatives, seeks rethink

The Indian Pharmaceutical Alliance (IPA) voices concerns over the government's ban on medical representatives in central hospitals, arguing it hinders knowledge dissemination and patient care. IPA urges a structured engagement model, citing potential impacts on pharmaceutical growth, job losses, and the introduction of new therapies. They emphasize the role of MRs in sharing crucial information and supporting evidence-based practice.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1F048lB
via IFTTT

Read More

Niti Aayog may prescribe major revamp of AIIMS Delhi

Niti Aayog is expected to propose a major overhaul of AIIMS Delhi, including expanding its clinical services across the NCR to ease infrastructure pressure and allow doctors to focus more on research. A VK Paul-led committee is preparing a blueprint to reform AIIMS to global standards, with plans to utilize other government or private hospital spaces for OPD services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yvkq1uz
via IFTTT

Read More

Glenmark to launch DCGI-approved cancer drug in India

Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies. Glenmark anticipates launching Brukinsa soon, in partnership with BeOne Medicines. This launch expands Glenmark's oncology offerings, providing Indian patients access to a globally recognized and effective therapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CzHT6jQ
via IFTTT

Read More

Advent International to acquire stake in Felix Pharmaceuticals

Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix Pharma, a Dublin-based company, specializes in generic animal pharmaceuticals, particularly for companion animals. With 14 USFDA-approved products and a robust pipeline, Felix aims to expand its global presence with Advent's support and expertise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U54rIpD
via IFTTT

Read More

KKR-backed IVI to buy ART Fertility clinics for $450 million

IVI RMA Global, backed by KKR, is poised to acquire ART Fertility Clinics for $400-450 million, marking a significant expansion into India's burgeoning IVF market. This acquisition will add India to IVI RMA's global presence. The deal highlights the ongoing consolidation in the Indian IVF sector, driven by increasing infertility rates and private equity investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hR5zyCE
via IFTTT

Read More

One cough too many: India's TB fight isn't quite there yet

Despite India's commitment to eliminate TB by 2025, the nation grapples with a significant burden of drug-resistant cases and underreporting. Stories like Anushka's highlight the challenges in accessing effective treatments and the critical need for improved diagnostics, funding, and equitable care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4SC7M3G
via IFTTT

Read More

API prices fall sharply, easing pressure on India's pharmaceutical industry

India's pharmaceutical industry is experiencing relief as active pharmaceutical ingredient (API) prices plummet due to overcapacity and aggressive pricing strategies from Chinese suppliers. Increased domestic API production, driven by government incentives and reduced raw material costs, further contribute to the decline. This trend is expected to continue, boosting profit margins for Indian pharma companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Opcv5mG
via IFTTT

Read More

Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iu2xyot
via IFTTT

Read More

Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe

Wockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europe. Following a successful pre-NDA meeting with the USFDA, the company plans to file for approval this quarter, aiming for a launch in FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SqXFZtA
via IFTTT

Read More

Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial cancer treatment with USD 29.5 billion in 2024 sales. The collaboration aims to expedite development and broaden global access to this biosimilar. Both companies will share development, manufacturing costs, and commercialization rights.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qnk9Xb3
via IFTTT

Read More

Avoid crowded places: Union Health Ministry amid surge in COVID-19 cases

India faces a rise in Covid-19 cases. The Health Ministry advises avoiding crowds and maintaining hygiene. Technical reviews and preparedness measures are underway. Surveillance for ILI and SARI has increased. Testing and genome sequencing are in progress. States are instructed to ensure resource availability. Mock drills are planned to assess oxygen supply. Individuals with respiratory illness should self-monitor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8937XDt
via IFTTT

Read More

Murae Organisor board to consider bonus issue, dividend payout next week

Murae Organisor's board will convene on June 13 to deliberate on a bonus issue of equity shares and dividend payment for FY25. The company is also eyeing strategic business expansion, including investments in agro and distillery sectors. Furthermore, Murae Organisor has set June 11 as the record date for its 1:2 stock split, reporting a revenue of Rs 854.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MWJ9itr
via IFTTT

Read More

IIT Delhi and AIIMS Delhi to establish AI centre for healthcare with Rs 330 crore grant

IIT Delhi and AIIMS Delhi have partnered to establish a Centre of Excellence for Artificial Intelligence in Healthcare (AI-CoE), supported by a ₹330 crore government grant. The centre aims to develop AI-driven solutions to enhance healthcare access and delivery across India, focusing on key national health programs. This initiative seeks to improve healthcare quality for remote and marginalized populations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J0b736o
via IFTTT

Read More

Ujjain to host Spiritual & Wellness Summit, showcasing India’s holistic future

Ujjain is set to host the Spiritual & Wellness Summit on June 5, drawing spiritual leaders, wellness experts, and policymakers. Madhya Pradesh Chief Minister Mohan Yadav will inaugurate the summit, highlighting Ujjain's spiritual legacy. Panel discussions will explore collaborative frameworks harmonizing traditional health systems with modern wellness innovations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tLrB8HU
via IFTTT

Read More

Biocon gets CDSCO nod for generic diabetes medication

Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly increasing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IeX23DK
via IFTTT

Read More

Medical representatives banned from visiting doctors in govt hospitals

The central government has banned medical representatives from directly meeting doctors in government hospitals to curb unethical practices and potential conflicts of interest. This decision aims to ensure doctors dedicate their time to patient care rather than promotional activities. The government encourages digital communication for sharing treatment advancements, reinforcing efforts to regulate pharmaceutical marketing practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wW5NqBd
via IFTTT

Read More

Glenmark’s blood cancer drug ISB 2001 shows promising results in trial

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xBID9qW
via IFTTT

Read More

Sanofi buys US biopharma group Blueprint in $9.1 billion deal

Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt, a drug for systemic mastocytosis. The acquisition also includes elenestinib and BLU-808, expanding Sanofi's pipeline. Blueprint shareholders will receive $129.00 per share in cash, plus contingent value rights for potential milestone payments related to BLU-808's development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S4WKIsZ
via IFTTT

Read More

Apollo Hospitals plans to sell maternity care arm

Apollo Hospitals Enterprises is planning to divest its maternity and infant care chain, Apollo Cradle and Children's Hospital (ACCHL). Allegro Capital has been appointed to find a buyer for ACCHL, with an estimated valuation of ₹1,000-1,200 crore. The sale process is underway, targeting leading private equity funds amidst a growing mother and child care market in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/az9KyWd
via IFTTT

Read More